Built In Staff, With AI

Our team uses Writer, a generative AI tool, to create relevant content for Built In users. This AI tool is used to supplement and support our existing editorial team.

Writer allows us to rapidly produce relevant and timely content for our readers and allows our team to focus on original reporting. Our editorial team remains committed to supporting the real people behind our stories.

All articles written using this tool are reviewed and fact-checked by a Built In editor.

Sort By
Most Recent
Most Recent
Oldest
49 Articles
Crop field being farmed
Four new hubs will facilitate regenerative agriculture research across various landscapes.
Greenery and office building
Miles Rice and Scott Hammes will oversee growth and business operations respectively.
Stethoscope on laptop
The name change is meant to highlight the company’s clinical and technical expertise.
microscope closeup
The AI-enabled precision medicine company began trading on the Nasdaq Global Select Market on June 14.
a flying plane
Kimberly Simonton and Florent Frapolli are joining the company with a collective five decades of experience.
Two hands reach across a table to shake. There are printouts with graphs all over the table.
The companies aim to develop protocols and analytics that ensure patient safety and quality of service.
Treated gypsum waste sits ready for use in industrial fillers and foams.
The company will use the funding to strengthen its partnerships with waste materials providers and make key hires across a number of teams.
Two glasses of wine sitting on a kitchen counter are pictured.
The company plans to enhance its platform and expand its team with the new capital.
An image of a question mark transitioning into a lightbulb is shown.
The program will feature expert mentorship, proof-of-concept testing and networking opportunities.
A person is pictured handing someone a box.
The company’s AI-powered platform helps businesses manage complex return processes.
A person typing on a laptop is shown.
Since its launch in 2022, Renterra has expanded its reach across the U.S. and Canada.
A close-up photo of a microscope is shown.
The company’s technology helps pathologists make more informed decisions while developing immunotherapies.